TY - JOUR
T1 - Humanin antagonists
T2 - Mutants that interfere with dimerization inhibit neuroprotection by Humanin
AU - Hashimoto, Yuichi
AU - Terashita, Kenzo
AU - Niikura, Takako
AU - Yamagishi, Yohichi
AU - Ishizaka, Miho
AU - Kanekura, Kohsuke
AU - Chiba, Tomohiro
AU - Yamada, Marina
AU - Kita, Yoshiko
AU - Aiso, Sadakazu
AU - Matsuoka, Masaaki
AU - Nishimoto, Ikuo
PY - 2004/5
Y1 - 2004/5
N2 - The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.
AB - The 24-residue peptide Humanin (HN) protects neuronal cells from insults of various Alzheimer's disease (AD) genes and Aβ by forming a homodimer. We have previously shown that P3A, S7A, C8A, L9A, L12A, T13A, S14A and P19A mutations nullify the neuroprotective function of HN [Yamagishi, Y, Hashimoto, Y., Niikura, T. & Nishimoto, I. (2003) Peptides, 24, 585-595]. Here we examined whether any of these 'null' mutants could function as dominant-negative mutants. Homodimerization-defective mutants, P3A-, L12A-, S14A- and P19A-HN, specifically blocked neuroprotection by HN, but not by activity-dependent neurotrophic factor. Furthermore, insertion of S7A, the mutation that blocks the homodimerization of HN, but not insertion of G5A abolished the antagonizing function of L12A-HN. While L12A-HN and G5A/L12A-HN actually inhibited HN homodimerization, S7A/L12A-HN had no effect. These data indicate that P3A-, L12A-, S14A- and P19A-HN function as HN antagonists by forming an inactive dimer with HN. This study provides a novel insight into the understanding of the in vivo function of HN, as well as into the development of clinically applicable HN neutralizers.
KW - Alzheimer's disease
KW - Dimerization
KW - Neuronal death
KW - Neuroprotection
UR - http://www.scopus.com/inward/record.url?scp=2942594839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2942594839&partnerID=8YFLogxK
U2 - 10.1111/j.0953-816x.2004.03298.x
DO - 10.1111/j.0953-816x.2004.03298.x
M3 - Article
C2 - 15128389
AN - SCOPUS:2942594839
SN - 0953-816X
VL - 19
SP - 2356
EP - 2364
JO - European Journal of Neuroscience
JF - European Journal of Neuroscience
IS - 9
ER -